Expression and clinical significance of heparanase in neuroblastoma

World Journal of Pediatrics

Volumn 5, Issue 3, 2009, Pages 206-210

  Zheng, Li Duan ^a   Tong, Qiang Song ^a   Tang, Shao Tao ^a   Du, Zhi Yong ^a   Liu, Yuan ^a   Jiang, Guo Song ^a   Cai, Jia Bin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Heparanase; Neuroblastoma; Risk; Survival

Indexed keywords

HEPARIN LYASE;

AGE; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS INDEX; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADRENAL GLAND NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDIASTINAL NEOPLASMS; NEUROBLASTOMA; RETROPERITONEAL NEOPLASMS;

EID: 69249164141     PISSN: 17088569     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12519-009-0039-9     Document Type: Article

References (22)

1. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, Li SW, et al. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008;4:58-62.
2. Pritchard J, Hickman JA. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994;344:869-870.
3. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006;118:1609-1617.
4. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004;96:1219-1230.
5. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018-2039.
6. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-372.
7. Kaneko M, Tsuchida Y, Uchino J, Takeda T, Iwafuchi M, Ohnuma N, et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma. J Pediatr Hematol Oncol 1999;21:190-197.
8. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
9. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001;95:295-301.
10. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003;83:613-622.
11. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003;14:1505-1510.
12. Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol 2005;131:229-237.
13. Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mössner J, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002;86:1270-1275.
14. Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, et al. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004;87:174-181.
15. Mikami S, Ohashi K, Katsube K, Nemoto T, Nakajima M, Okada Y. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas. Pathol Int 2004;54:556-563.
16. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455-1463.
17. Okawa T, Naomoto Y, Nobuhisa T, Takaoka M, Motoki T, Shirakawa Y, et al. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin Cancer Res 2005;11:7995-8005.
18. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-292.
19. Nobuhisa T, Naomoto Y, Okawa T, Takaoka M, Gunduz M, Motoki T, et al. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci 2007;98:535-540.
20. He X, Brenchley PE, Jayson GC, Hampson L, Davies J, Hampson IN. Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res 2004;64:3928-3933.
21. Ishida K, Hirai G, Murakami K, Teruya T, Simizu S, Sodeoka M, et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol Cancer Ther 2004;3:1069-1077.
22. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999;83:424-431.